 "Rallis India's arm Metahelix forms JV in Indonesia for seeds business")
Rallis India, the agrochemicals company of Tata Group, has formed a joint venture in Indonesia for expanding its seeds business in the region.
“Metahelix Life Sciences Limited (Metahelix), a wholly-owned subsidiary of Rallis India, has entered into a joint venture with Indonesian local partner, Suresh Gobindram Vaswani, for the establishment of a seed production and/or distribution company, PT Metahelix Lifesciences Indonesia,” said Rallis India in a BSE filing yesterday.
While Metahelix will hold 49 percent stake in the JV firm PT Metahelix Lifesciences Indonesia, the remaining will be with its partner. With this venture, Rallis aims to avail opportunities for expansion of Metahelix’s seeds business in relevant crops in South East Asia.
Metahelix, based at Bangalore, is an agricultural biotechnology company focusing on developing traits and technologies for crop protection and improved productivity. It also provides customised research to select global agri-biotech business using its proprietary technologies in crop transformation and functional genomics.
“Metahelix Life Sciences Limited (Metahelix), a wholly-owned subsidiary of Rallis India, has entered into a joint venture with Indonesian local partner, Suresh Gobindram Vaswani, for the establishment of a seed production and/or distribution company, PT Metahelix Lifesciences Indonesia,” said Rallis India in a BSE filing yesterday.
While Metahelix will hold 49 percent stake in the JV firm PT Metahelix Lifesciences Indonesia, the remaining will be with its partner. With this venture, Rallis aims to avail opportunities for expansion of Metahelix’s seeds business in relevant crops in South East Asia.
Metahelix, based at Bangalore, is an agricultural biotechnology company focusing on developing traits and technologies for crop protection and improved productivity. It also provides customised research to select global agri-biotech business using its proprietary technologies in crop transformation and functional genomics.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%